Changes in 19fe67f: add BTK clinical

				BTK.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Clinical Relevance

          -The BTK inhibitor Imbruvica (Ibrutinib) had prior FDA approval for use in MCL and MZL which has since been [withdrawn](https://www.drugs.com/history/imbruvica.html) because *primary outcomes from the confirmatory Phase 3 studies studies were considered insufficient to support conversion to full approval.* There are some data suggesting a subset of DLBCL patients (with certain genetic features) may benefit from the combination of Ibrutinib with R-CHOP [@wilsonEffectIbrutinibRCHOP2021]. There is no known relevance between BTK mutations and the activity of BTK inhibitors.

          +The BTK inhibitor Imbruvica (Ibrutinib) had prior FDA approval for use in MCL and MZL which has since been [withdrawn](https://www.drugs.com/history/imbruvica.html) because *primary outcomes from the confirmatory Phase 3 studies studies were considered insufficient to support conversion to full approval.* There are some data suggesting a subset of DLBCL patients (with certain genetic features) may benefit from the combination of Ibrutinib with R-CHOP [@wilsonEffectIbrutinibRCHOP2021]. 

           ## Relevance tier by entity

...	...	@@ -15,7 +15,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons
15	15
16	16	## Clinical Relevance
17	17
18		-The BTK inhibitor Imbruvica (Ibrutinib) had prior FDA approval for use in MCL and MZL which has since been [withdrawn](https://www.drugs.com/history/imbruvica.html) because primary outcomes from the confirmatory Phase 3 studies studies were considered insufficient to support conversion to full approval. There are some data suggesting a subset of DLBCL patients (with certain genetic features) may benefit from the combination of Ibrutinib with R-CHOP [@wilsonEffectIbrutinibRCHOP2021]. There is no known relevance between BTK mutations and the activity of BTK inhibitors.
	18	+The BTK inhibitor Imbruvica (Ibrutinib) had prior FDA approval for use in MCL and MZL which has since been [withdrawn](https://www.drugs.com/history/imbruvica.html) because primary outcomes from the confirmatory Phase 3 studies studies were considered insufficient to support conversion to full approval. There are some data suggesting a subset of DLBCL patients (with certain genetic features) may benefit from the combination of Ibrutinib with R-CHOP [@wilsonEffectIbrutinibRCHOP2021].
19	19
20	20	## Relevance tier by entity
21	21